FiercePharmaOriginal article
{"a":[{"_":"Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling","$":{"href":"/pharma/amgen-rides-repatha-renaissance-cardio-wins-keep-cholesterol-meds-momentum-rolling","hreflang":"en"}}]}
Data ReadoutpositiveRepathaPositive
AI Analysis
Summary
Amgen's Repatha cholesterol drug is experiencing renewed momentum following impressive cardiovascular risk reduction data from last year, with the company expressing confidence in maintaining strong performance through the end of the decade.
Outcome Details
impressive cardiovascular risk reduction data
Importance:6/10
Sentiment:
0.70
PCSK9 inhibitorcholesterolcardiovascularclinical datamarket momentum
Related Companies
Read the original article
Published by FiercePharma on August 4, 2026 1:51 PM
